An evidence-based approach to clinical practice guidelines: diagnosis and treatment of irritable bowel syndrome1
The Institute of Medicine defines clinical practice guidelines as “systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”1 In other words, clinical practice guidelines may offer clear recommendations about the utility of diagnostic tests and the efficacy of different treatments for specific disorders. Guidelines have been promoted as tools that enhance the quality of medical care by reducing practice variations, minimizing spending on unnecessary diagnostic tests, and preventing the use of ineffective treatments.2 During the past decade, the number of published guidelines has increased exponentially. The Agency of Health Care Research and Quality established a National Guidelines Clearinghouse website, which lists hundreds of guidelines. Although it is in vogue to state that a guideline is evidence-based, most guidelines are developed from the consensus opinion of experts. An evidence-based guideline usually consists of multiple systematic reviews about the diagnosis and treatment of a disorder. These systematic reviews should meet rigorous criteria for the critical appraisal of clinical research on which the guidelines for diagnosis and treatment are based. Nevertheless, expert opinion is still important in evidence-based guidelines because these experts are called on to render an opinion when there simply are no data. Experts also provide guidance about the implementation of evidence-based recommendations!
∗Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
‡Veterans Affairs Center for Excellence in Health Services Research, Ann Arbor, Michigan, USA
Address requests for reprints to: Philip Schoenfeld, M.D., MSEd, MSc (Epi), Division of Gastroenterology (111D), VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, Michigan 48105, USA. fax: (734) 761-5260.
1 The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Veterans Affairs.
2 Dr. Schoenfeld is a consultant for Novartis Pharmaceuticals Corporation, Proctor and Gamble, and AstraZeneca LP. Dr. Schoenfeld is on the Speakers Bureau for AstraZeneca LP, Wyeth Laboratories, TAP Pharmaceuticals, Novartis Pharmaceuticals Corporation, Boehringer Ingleheim, and Merck. Dr. Chey is a consultant for Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, and AstraZeneca LP. Dr. Chey has received research support from Novartis Pharmaceuticals Corporation, TAP Pharmaceuticals, AstraZeneca LP, and Janssen. Dr. Chey is on the Speakers Bureau for Novartis Pharmaceutical Corporation, AstraZeneca LP, TAP Pharmaceuticals, and Janssen.